Phibro Animal Health Corporation (PAHC) fair value analysis
Nasdaq · Updated 2026-10-19
PAHC price how computed
Forward Fair Value verdict
UndervaluedPAHC is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $38.82
- Sector
- Healthcare
- 12-month range
- $28.52–$59.58
- Market cap
- $1.58B
- From 52-week high
- -34.8%
- Shares outstanding
- 40.6M
- Rank in Healthcare by discount to fair value
- #37 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Phibro Animal Health Corporation is a company that develops, manufactures, and distributes products for animal health and nutrition. The company operates globally, serving customers in livestock, poultry, and aquaculture industries across multiple regions.
PAHC currently ranks #37 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $1.58B
- P/E (trailing)
- 12x
- Revenue (TTM)
- $1.52B
- Net margin
- 6.6%
- EPS (TTM)
- $3.21
- Gross margin
- 33.9%
- Debt / equity
- 2.05
- Revenue growth (3-yr avg)
- 23.8%
- Shares outstanding
- 40.6M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 69 · neutral
- 50-day average
- $36.11
- 200-day average
- $41.27
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $0.48 per share (4 payments)
- Yield on last price
- 1.24%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-09-02
- Last payment date
- 2026-09-23
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+18.1%)
2026-03 ▲ beat (+7.0%)
2025-12 ▲ beat (+29.9%)
2025-09 ▲ beat (+23.7%)
2025-06 ▲ beat (+9.6%)
2025-03 ▲ beat (+21.2%)
2024-12 ▲ beat (+20.0%)
2024-09 ▲ beat (+40.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 1 buy · 2 hold · 1 sell (4 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $47
- Target vs last price
- +21.1%
What our data shows for PAHC
- Our model validated 17 trailing price-to-earnings windows for PAHC, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $28.52–$59.58.
- The 14-day relative strength index sits at a neutral 69.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for PAHC
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent PAHC news
TickrTrends' derived news-sentiment signal for PAHC is currently leaning positive, computed from recent coverage.
- Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year (finance.yahoo.com, 2026-09-01)
TickrTrends take: Phibro Animal Health has now completed its first full year following a significant acquisition, providing investors with the initial results needed to assess whether the company paid a fair price for the deal. Given TickrTrends' current assessment that PAHC trades at an undervalued level, readers should monitor whether the acquired assets generate sufficient earnings and cash flow to justify the acquisition price and support any multiple expansion. The healthcare sector investor watching this stock should track whether management's integration efforts translate into margin improvements or revenue synergies that could narrow any valuation gap. - Phibro’s (PAHC) Big Acquisition Bet Just Cleared Its First Full Year (insidermonkey.com, 2026-09-01)
TickrTrends take: Phibro Animal Health Corporation has completed its first full year following a significant acquisition, providing investors with their first comprehensive view of how the combined entity is performing operationally and financially. TickrTrends currently identifies PAHC as undervalued within the Healthcare sector, suggesting that market pricing may not yet fully reflect the integration progress or earnings potential from this major deal. Valuation-focused readers should monitor whether upcoming quarterly results demonstrate that the acquisition is delivering expected synergies and revenue growth, which could validate or challenge the current undervalued assessment. - Phibro Animal Health Corporation 2026 Q4 - Results - Earnings Call Presentation (NASDAQ:PAHC) 2026-08-31 (seekingalpha.com, 2026-08-31)
TickrTrends take: Phibro Animal Health Corporation's latest quarterly results come as TickrTrends currently assesses the stock as undervalued within the Healthcare sector, suggesting the market may not be fully pricing in the company's earnings performance. Investors focused on valuation metrics should examine whether the company's recent financial results support the undervalued designation or indicate changing fundamentals that warrant recalibration. The earnings call presentation provides an opportunity to evaluate management's guidance and operational efficiency against the current market valuation.
What people are saying
Follow the PAHC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — TickrTrends' indicators for PAHC showed mixed movement this week. The 50/200-day trend state shifted from downtrend to mixed, while momentum declined from C-rated to none, and the stock's sector discount rank weakened from 39th to 48th position among healthcare peers. Despite these indicator changes, PAHC maintains an undervalued valuation verdict.
- 2026-09-28 — TickrTrends' derived indicators for PAHC show a shift toward weaker momentum this week, with the 50/200-day trend state moving from mixed to downtrend. The stock's sector discount rank improved to 39 from 49, indicating it now trades at a better relative valuation within the Healthcare sector. PAHC maintains an undervalued verdict according to current valuation analysis.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is PAHC stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), PAHC is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is PAHC's TickrTrends verdict?
PAHC's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does PAHC compare to other Healthcare stocks?
PAHC ranks #37 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is PAHC overbought or oversold?
PAHC's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does PAHC pay a dividend?
Yes. PAHC paid $0.48 per share over the last twelve months (4 payments), a 1.24% yield on TickrTrends' last price. The last ex-dividend date was 2026-09-02.
When does PAHC report earnings next?
PAHC's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does PAHC usually beat earnings estimates?
Over its last 8 reported quarters PAHC beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PAHC?
Of 4 analysts covering PAHC, 1 rate it a buy, 2 a hold and 1 a sell - hold-leaning, with a consensus price target of $47 (+21.1% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
PAHC vs BAX · PAHC vs BDX · PAHC vs BTSG · PAHC vs EW · PAHC vs HALO